Notably, co-inhibition of BCL2 and MCL1 in vitro partially abrogated observed resistance in TP53-mutated AML, suggesting combined anti-apoptotic protein inhibition could be effective in this high-risk patient subgroup [29]. Here, MCL1 is linked to acute myeloid leukemia.